Lipidomics analysis to assess metabolic complications in familial partial lipodystrophy type 2
A new metabolic scoring tool may better identify hidden health risks in rare lipid disorder patients who look healthy by conventional measures.
This case-control lipidomics study (n=115 FPLD2 + 289 controls; 787 lipid species) characterizes the metabolic signature of familial partial lipodystrophy type 2, a rare severe metabolic syndrome, revealing a lipidomic profile overlapping with T2DM and identifying a novel mBMI score that captures metabolic risk in FPLD2 patients who appear metabolically normal by conventional BMI. The mBMI tool may improve clinical risk stratification and therapeutic monitoring for this rare, high-unmet-need disease.
What the study was
- Study design
- Case-control lipidomics study (787 lipid species, LC-tandem mass spectrometry)
- Population
- Adults with FPLD2 (LMNA 'Reunionese' variant, n=115) and age/sex matched controls (n=289)
- Sample size
- 404
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Diabetes Research and Clinical Practice
Why it surfaced
First lipidomics characterization of FPLD2 Reunionese variant (n=115); rare disease with high unmet metabolic need; mBMI tool has practical clinical utility for identifying at-risk FPLD2 patients with normal conventional BMI.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.